See every side of every news story
Published loading...Updated

SYSA1902 Clinically Equivalent to Ustekinumab for Plaque Psoriasis

Summary by hcplive.com
Ustekinumab and its generic biofamailiar SYSA1902 exhibited clinical equivalence in terms of safety, efficacy, pharmacokinetics, and immunogenicity.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

hcplive.com broke the news in on Wednesday, April 16, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.